FDA grants Sanofi's blockbuster priority review in a new indication

Sanofi’s drug Dupixent has now received the US health authority’s Breakthrough Therapy, Orphan Drug and Priority Review designations, the latter of which in a new indication for people with inflamed esophagi due to allergies.

Photo: Benoit Tessier/Reuters/Ritzau Scanpix

French Sanofi has been granted Priority Review by the US Food and Drug Administration (FDA) for Dupixent (dupilumab) in the indication for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus, the company has announced in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs